About: Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) artículu científicu espublizáu en mayu de 2019 (ast) scientific article published on 01 May 2019 (en) im Mai 2019 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована 1 травня 2019 (uk)
publication date	wds:Q90626791-9A2A8867-FDC3-49A0-A4F6-E99D7CBEAF81
publication date	2019-05-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q90626791-0DC4B9F3-8199-4083-87B3-B7B8042FFA1E wds:Q90626791-1629C476-6C9F-4C3F-8E19-D1AEBD1A5EC9 wds:Q90626791-1D4DC569-CF3B-4BBA-9531-D6D5A9425F82 wds:Q90626791-31816B98-F6F3-454F-A03F-5DCFD477C7DC wds:Q90626791-38258DD5-695C-4F8E-A055-39B09B1ADB42 wds:Q90626791-3862BFFC-021F-41FD-AA63-AECCAE74538A wds:Q90626791-39282ED6-BF0F-4CC4-9995-E4BE9A5A82EB wds:Q90626791-3F40080B-401A-4022-B704-8F59AD2C62A3 wds:Q90626791-3FE9593F-FE2D-4C70-A004-1D8153517AF2 wds:Q90626791-47D46C86-C8E3-48CA-AEA3-8FF6A0069390 wds:Q90626791-5D9380FA-DAB2-4C4A-AF51-9829546DF036 wds:Q90626791-69677BBD-FF38-4C2C-8D6C-7971C6143D04 wds:Q90626791-699CC9BA-2DD6-43CF-8719-77B9CA16FC88 wds:Q90626791-734378AC-20EE-4AD5-ADA7-C87DDE265DDB wds:Q90626791-7A12E5B3-3006-4F3A-9C7E-802FE11C7305 wds:Q90626791-7FEA2CEC-855F-4898-ACFF-392122FEFD02 wds:Q90626791-88ADE99B-1562-48E0-BD80-A43090EDC661 wds:Q90626791-9F6B98D9-6D15-4E2F-960C-501704C5AFAE wds:Q90626791-A0D000C5-BA3E-4306-8D62-FC065CB4AA03 wds:Q90626791-AB1063D6-13FF-4B20-931D-55283D5448F7 wds:Q90626791-B055A77D-E2D3-4BD5-BBFA-77562BE128C2 wds:Q90626791-BFC760C0-8BF6-4F0C-A0D7-C5B5C34425AF wds:Q90626791-CC96E4A7-7AEB-4009-A2C3-229A76273100 wds:Q90626791-D0D31C9F-AEFA-449E-9F86-E40FEA1F7FD4 wds:Q90626791-D13B00B6-E437-4506-9EA2-2DA6CB3A0DCD wds:Q90626791-D1D25D41-9DB7-456C-81AB-8D72186010AF wds:Q90626791-D3FA345E-AEE1-4FD7-A74C-1BD1ADCA197D wds:Q90626791-D9C8EF20-CE96-4D1C-AB95-FEA57AAF7FF4 wds:Q90626791-E091D34B-B050-468E-835A-CB69BD8FBF25 wds:Q90626791-E5BC99ED-A1C0-4C12-BA20-BA0DF233F79F wds:Q90626791-ED0F19A5-6318-4D36-AD53-F50AF0CC8961 wds:Q90626791-FC084D50-3B4E-4ED2-B167-0D871220C3B8
cites work	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Blinatumomab: a historical perspective Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Rare cancers are not so rare: the rare cancer burden in Europe. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter S Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Bispecific antibodies and their applications Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications Adult acute lymphoblastic leukemia: concepts and strategies International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration Outcome of adults with acute lymphocytic leukemia after second salvage therapy Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia Serum immunoglobulins and risk of infection: how low can you go? The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders. New developments in immunotherapy for pediatric leukemia. Adult Acute Lymphoblastic Leukemia Diagnosis and classification of hematologic malignancies on the basis of genetics. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Acute Lymphoblastic Leukemia, Version 2.2015. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.
author name string	wds:Q90626791-1AF08EAB-1DD1-4DCE-B733-683B1CA71EAD wds:Q90626791-29C04BF1-ACAE-4AEA-B393-F5BD48F30875 wds:Q90626791-2A79B2E3-FBAB-4268-99FA-1EDF63C7BFAA wds:Q90626791-2A87561F-232E-47EC-B135-D5DBD61E50A1 wds:Q90626791-3B0CDE67-97CE-4115-A14F-C48B38271CA5 wds:Q90626791-5D6E844F-9BE8-4D5C-9668-68DCA12FD646 wds:Q90626791-62601D9F-5CF2-4DBC-AD1C-F369479054E6 wds:Q90626791-711A7874-6A6F-4956-8787-CCDA3C52C26F wds:Q90626791-E454ADE0-4FDD-4918-A7F7-751E940CF21A wds:Q90626791-E5BB53F1-CF20-4579-A89D-FDB7E4BA668C
author name string	Anthony Stein Victoria M Chia Guiandre Joseph Hamid R Amouzadeh Mandy Parson Janet L Franklin Jacqueline Wright Deborah Arrindell William Kormany Jessica Choudhry
rdfs:label	Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (en) Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (nl)
skos:prefLabel	Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (en) Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (nl)
name	Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (en) Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (nl)
title	wds:Q90626791-338AD1B1-AFB3-4D4F-9800-BFCD1B8E374F
title	Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software